Scaling Up for First Product Launch: Seven Hazards to Avoid Pierre Jacquet, M.D., Ph.D. Peter Rosenorn Aditya Natarajan Read more
Related Practice Life Sciences & Pharma As the margin for error in the drug launch cycle continues to erode, emerging biopharma companies face a growing urgency to double down on scaling up for that first launch. 01022024150106
Podcast Life Sciences & Pharma A New Generation of Drug Therapies Requires New Business Strategies July 10, 2024
Published Articles Marketing & Sales How Can Businesses Survive the ‘Cookie Apocalypse’? April 25, 2024
Published Articles Digital Embracing AI: A Guide for CEOs to Lead the Digital Charge January 31, 2024
Article Life Sciences & Pharma The SEA Healthcare, Medtech, and Pharma Landscape in 2023 December 7, 2023